DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
4G7XH22
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Lymphoma
Unknown
4G7XH22
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAVURUTAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PAVURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-7184
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-7184
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELUVIXTAMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Unknown
ELUVIXTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANELIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MANELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
U3OZ7HX207
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAR-1349
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SAR-1349
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
FORAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
377VY97V7S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-167
1
Antibody
Investigational
Unknown
Unknown
Bone Diseases, Metabolic
Sclerostin inhibitor
AMG-167
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUMRETUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms
Receptor tyrosine-protein kinase erbB-3 inhibitor
LUMRETUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
Y6M3205516
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELGEMTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms
Receptor tyrosine-protein kinase erbB-3 inhibitor
ELGEMTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5F1CN52GFM
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-191
1
Antibody
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Stem cell growth factor receptor inhibitor
AMG-191
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VESENCUMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Neuropilin-1 inhibitor
VESENCUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
7SF22186WT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-729
1
Antibody
Investigational
Unknown
Unknown
Unknown
B-lymphocyte antigen CD19 binding agent
AMG-729
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOC31-PE
1
Antibody
Investigational
Unknown
Unknown
Carcinoma
Epithelial cell adhesion molecule binding agent
MOC31-PE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DATOPOTAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DATOPOTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUDIGALIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma
Programmed cell death protein 1 inhibitor
BUDIGALIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
6VDO4TY3OO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CM-101
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CM-101
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SC-1
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SC-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CYT-500 177LU
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms
Glutamate carboxypeptidase II binding agent
CYT-500 177LU
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLANVOTUMAB
1
Antibody
Investigational
Unknown
Unknown
Melanoma
5,6-dihydroxyindole-2-carboxylic acid oxidase other
FLANVOTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
ZNV4738BS6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLN-2704
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
MLN-2704
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIK-BETA-1
1
Antibody
Investigational
Unknown
Unknown
Leukemia
Interleukin-2 receptor beta chain inhibitor
MIK-BETA-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-015
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Teratocarcinoma-derived growth factor 1 binding agent
BIIB-015
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDIUM IN 111 ALTUMOMAB PENTETATE
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
INDIUM IN 111 ALTUMOMAB PENTETATE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONVATILIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
ONVATILIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
1UI8F5IIZ4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
E2.3
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders
Transferrin receptor inhibitor
E2.3
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ULOCUPLUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Multiple Myeloma; Neoplasms; Waldenstrom Macroglobulinemia
C-X-C chemokine receptor type 4 inhibitor
ULOCUPLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
7KNP87L4X4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-61186372
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
JNJ-61186372
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUMILIXIMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell
Immunoglobulin epsilon Fc receptor antagonist
LUMILIXIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
8Z13S29R5A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UBAMATAMAB
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms
Unknown
UBAMATAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MILATUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Plasmacytoma
HLA-DR antigens-associated invariant chain antagonist
MILATUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
2OP4E0GC6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7594
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-7594
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
4
5
6
7
8
9
10
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA